Published in JCI Insight on October 20, 2016
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol (2002) 35.63
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 8.29
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A (1997) 4.17
Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A (1999) 3.07
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science (2016) 1.90
The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol (2003) 1.80
Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol (2002) 1.61
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med (1992) 1.48
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol (2003) 1.35
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol (2005) 1.16
Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia. J Clin Endocrinol Metab (2009) 1.15
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol (2010) 1.09
Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol (1994) 1.06
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol (2011) 1.02
The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets (2011) 1.00
Pembrolizumab: first global approval. Drugs (2014) 0.99
Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.98
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett (2005) 0.93
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol (1999) 0.92
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther (2014) 0.91
Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Genet (2009) 0.90
PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother (2014) 0.80
Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS One (2014) 0.77
Association of the Lipoprotein Receptor SCARB1 Common Missense Variant rs4238001 with Incident Coronary Heart Disease. PLoS One (2015) 0.77
The Genetic Landscape of Renal Complications in Type 1 Diabetes. J Am Soc Nephrol (2016) 1.44
Co-occurrence of Type 1 Diabetes and Celiac Disease Autoimmunity. Pediatrics (2017) 0.75
Fine-mapping of QT regions in global populations refines previously identified QT loci and identifies signals unique to african and hispanic descent populations. Heart Rhythm (2016) 0.75
Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification. J Am Coll Cardiol (2017) 0.75